
SRRA
Healthcare · Biotechnology · $1.34B market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2022
EPS trend, 90 days to now · +10.4% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 6, 2022 | Before the open | -1.03 | -1.33 | -29.1% |
| Mar 10, 2022 | Before the open | -1.54 | -1.67 | -8.4% |
| Nov 5, 2021 | Before the open | -1.78 | -2.10 | -18.0% |
| Aug 5, 2021 | After the close | -1.61 | -1.67 | -3.7% |
| May 7, 2021 | Before the open | -1.60 | -1.71 | -6.9% |
| Mar 11, 2021 | Before the open | -1.52 | -1.63 | -7.2% |
| Nov 5, 2020 | Before the open | -1.64 | -1.39 | +15.2% |
| Aug 6, 2020 | Before the open | -1.63 | -1.58 | +3.1% |
| May 7, 2020 | Before the open | -2.74 | -3.14 | -14.6% |
| Mar 3, 2020 | Before the open | -3.16 | -7.88 | -149.4% |
| Nov 4, 2019 | After the close | -8.40 | -6.80 | +19.0% |
| Aug 8, 2019 | Before the open | -7.87 | -8.00 | -1.7% |
| May 8, 2019 | Before the open | -8.27 |
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective…
| -6.80 |
| +17.8% |
| Feb 28, 2019 | Before the open | -8.27 | -7.60 | +8.1% |
| Nov 8, 2018 | Before the open | -7.03 | -8.40 | -19.5% |
| Aug 9, 2018 | Before the open | -6.53 | -6.40 | +2.0% |
| May 10, 2018 | Before the open | -8.53 | -7.60 | +10.9% |
| Feb 27, 2018 | Before the open | -8.13 | -8.00 | +1.6% |